News | February 12, 2015

Pocket ECG Supports Study by Texas Cardiac Arrhythmia Research Foundation

Study investigating impact of lifestyle modification on ablation outcome in atrial fibrillation

February 12, 2015 — Medi-Lynx Cardiac Monitoring LLC and Medicalgorithmics have announced their participation in a research project investigating the impact of lifestyle modification on ablation outcome in atrial fibrillation (ISOLATE).  Medicalgorithmics’ PocketECG cardiac monitoring system will be used for collecting and analyzing the electrocargiogram (ECG) data in the project.

The research started in August 2014, financed by Texas Cardiac Arrhythmia Research Foundation. It will evaluate the impact of aggressive lifestyle modification, in terms of calorie-controlled diet and supervised exercise, on outcomes of catheter ablation in overweight and obese patients with atrial fibrillation. The hypothesis states that weight loss and management by adoption of a strict diet and exercise regimen improves the chances of freedom from recurrence following catheter ablation.

The PocketECG system recognizes the morphology of each individual heartbeat and allows differentiating between normal and abnormal heartbeats including ventricular ectopy, supraventricular ectopy, aberrated supraventricular beats, artifact, etc. This functionality combined with the capability of streaming the continuous ECG for many weeks provides reliable Heart Rate Variability statistics over an extended monitoring period.  The system also has the ability to calculate detailed arrhythmia statistics for extended monitoring sessions and to identify HRV changes and morphology of each individual QRS complex.

The study’s eligible group is overweight or obese adult patients with a diagnosis of atrial fibrillation undergoing first catheter ablation at least three months after the enrollment. Supervised and monitored exercise will be conducted in St. David's Cardiac Rehabilitation for at least three months before ablation. After ablation, patients will continue an individualized home-exercise program for one year.

For more information: www.medicalgorithmics.com


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now